Faes Farma SA 2024 AR2
The report details Faes Farma's financial and operational performance for the fiscal year 2024, highlighting a deep transformation under its new CEO, Eduardo Recoder. The company achieved record financial results with ‑510 million in total revenues and ‑111.4 million in net profit, driven by strong pharmaceutical sales in Spain and international expansion. In sustainability, Faes Farma advanced its 'Positive Impact' pillar, achieving 52% renewable energy usage globally and reaching gender parity on its Board of Directors. Additionally, the company completed major investments in its new Derio pharmaceutical plant and Huesca animal nutrition facility to support future growth.
Company: Faes Farma SA
Sector: Health Care
Country: Spain
Year: 2024
Type: AR2
Pages: 108
Faes Farma SA
Consolidated Annual Accounts
The report details Faes Farma's financial and operational performance for the fiscal year 2024, highlighting a deep transformation under its new CEO, Eduardo Recoder. The company achieved record financial results with ‑510 million in total revenues and ‑111.4 million in net profit, driven by strong pharmaceutical sales in Spain and international expansion. In sustainability, Faes Farma advanced its 'Positive Impact' pillar, achieving 52% renewable energy usage globally and reaching gender parity on its Board of Directors. Additionally, the company completed major investments in its new Derio pharmaceutical plant and Huesca animal nutrition facility to support future growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women on Board
Women in Management
Employees